Key result
Antiplatelet agents, including aspirin, ticlopidine, clopidogrel, and aspirin with extended-release dipyridamole, are reviewed for their efficacy and guideline recommendations in stroke prevention.
Population
Patients with transient ischemic attack or noncardiogenic ischemic stroke
Design
Review
Authors
Loading...
Supports guideline-directed antiplatelet use for secondary stroke prevention; leaves open comparative effectiveness questions in contemporary subgroups.
This review provides an update on antiplatelet agents and current guidelines for their use in preventing recurrent stroke in patients with TIA or noncardiogenic ischemic stroke.
Neill et al. (2002) conducted a review in transient ischemic attack or noncardiogenic ischemic stroke. Antiplatelet therapy (aspirin, ticlopidine, clopidogrel, aspirin and extended-release dipyridamole) was evaluated. Antiplatelet agents, including aspirin, ticlopidine, clopidogrel, and aspirin with extended-release dipyridamole, are reviewed for their efficacy and guideline recommendations in stroke prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: